The agency first approved Orkambi in 2015 for cystic fibrosis patients age 12 and older. Now, the drug can also be used to treat children ages 6 to 11.
Despite the approval, Boston-based Vertex lowered its 2016 sales forecast for the drug from about $1 billion to no more than $990 million.
More articles on supply chain:
US consumer confidence index at highest level in 9 years
Drug reviewers often ditch FDA for pharma industry, research finds
Why patient advocacy groups are silent about high drug prices
